Harrow Health Inc (HROW)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
HROW
Harrow Health Inc
$36.35
+3.27%
HEALTHCARE · Cap: $2.01B
TAK
Takeda Pharmaceutical Co Ltd ADR
$18.29
+1.39%
HEALTHCARE · Cap: $56.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 1785431% more annual revenue ($4.46T vs $250.04M). TAK leads profitability with a 2.5% profit margin vs -2.0%. TAK earns a higher WallStSmart Score of 60/100 (C).
HROW
Hold37
out of 100
Grade: F
TAK
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HROW.
Margin of Safety
-77.5%
Fair Value
$10.30
Current Price
$18.29
$7.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 45.4% year-over-year
Strong operational efficiency at 20.6%
Growing faster than its price suggests
Reasonable price relative to book value
Generating 317.5B in free cash flow
Large-cap with strong market position
Areas to Watch
Trading at 28.6x book value
ROE of -9.6% — below average capital efficiency
Earnings declined 64.0%
Currently unprofitable
4.2% revenue growth
3.3% earnings growth
ROE of 1.5% — below average capital efficiency
2.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : HROW
The strongest argument for HROW centers on Revenue Growth, Operating Margin. Revenue growth of 45.4% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.39 suggests the stock is reasonably priced for its growth.
Bear Case : HROW
The primary concerns for HROW are Price/Book, Return on Equity, EPS Growth.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, EPS Growth, Return on Equity. A P/E of 82.0x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
HROW profiles as a hypergrowth stock while TAK is a value play — different risk/reward profiles.
TAK carries more volatility with a beta of 0.10 — expect wider price swings.
HROW is growing revenue faster at 45.4% — sustainability is the question.
TAK generates stronger free cash flow (317.5B), providing more financial flexibility.
Bottom Line
TAK scores higher overall (60/100 vs 37/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Harrow Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?